新闻发布 HUYABIO International Announces Initiation of HBI-3000 Phase 2 TrialHUYABIO International Announces Completion of HBI-3000 Phase 1 Trial and FDA Approval to Proceed With Dose Escalation in Phase 2HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare PharmaceuticalHUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in JapanHUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai PharmaceuticalsHUYABIO International Announces Initiation of Phase 2 Atrial Fibrillation TrialHUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated TumorsHUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in JapanHUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced MelanomaHUYABIO Files an Investigational New Drug Application with the FDA for the Novel SHP2 Inhibitor HBI-2376HUYABIO Announces HBI-8000 Brand Name of Hiyasta™HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in JapanHUYABIO International Submits HBI-8000 Monotherapy for Peripheral T-cell Lymphoma for Regulatory Approval in JapanHUYABIO International Announces Global Clinical Trial Collaboration with Bristol Myers Squibb in Melanoma沪亚生物国际宣布与百时美施贵宝在黑色素瘤领域开展全球临床试验合作HUYABIO International and Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese New Drug Application for Efinaconazole as Jublia™HUYA Bioscience International Presents Positive Data on HBI-8000 at Society for Immunotherapy of Cancer MeetingHUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in JapanHUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in JapanHUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in OncologyHUYA Bioscience International Announces the Successful Completion of Phase 1 Trial of HBI-3000HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian CountriesHUYA Bioscience International Expanded Oncology Pipeline Includes Combination with Checkpoint Inhibitor for Solid TumorsHUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOPHUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic CollaborationHUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ CategoryHUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016HUYA Bioscience International Celebrates 10 Years in ChinaHUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in JapanHUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP AwardsHUYA Bioscience International Expands into South KoreaHUYA Bioscience International Announces a Strategic Alliance with the Korea Drug Development FundHUYA Bioscience International Celebrates its 10th AnniversaryHUYA Bioscience International and TechCode Gu’an Lifesciences Park Establish Strategic CollaborationHUYA Bioscience International Further Expands Executive TeamHUYA Bioscience International Sponsors Japan Society of HTLV-1 Annual MeetingHUYA Bioscience International CEO, Mireille Gillings, Ph.D., Named As Gold Award Winner In 2015 American Business AwardsHUYA Bioscience International Wins Bronze Stevie® Award In 2015 Asia-Pacific Stevie AwardsHUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In JapanHUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In ChinaHUYA Bioscience International Is The First To Leverage Tripartite CooperationHUYA Bioscience International Establishes Alliance With China Wuqing Development AreaHUYA Bioscience International And TIPR Announce Joint Venture To Develop Medical Innovation For Global MarketsHUYA Bioscience International Announces Partnership with Changzhou Center for Biotech DevelopmentHUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical BaseHUYA Bioscience Announces New Partnership With Tianjin Research Center Of Basic Medical SciencesHUYA Bioscience Announces New Partnership With A High Profile Pharmaceutical Lab At Shanghai’s Prestigious Fudan UniversityHUYA Bioscience International Announces Strategic Partnership With The Tianjin Institute Of Pharmaceutical ResearchHUYA Bioscience International Builds Long-Term Relationship With Shenzhen Polytechnic School Of Applied Chemistry And BiotechnologyHUYA Bioscience International And Tianjin International Joint Academy Of Biotechnology And Medicine Form AllianceHUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science CollegeHUYA Bioscience International Engages In Partnership With Liaoning (Benxi) Bio-Pharmaceutical Industry BaseHUYA Bioscience And Wuhan Biolake Form Alliance To Help Accelerate China’s Bio-Industry DevelopmentHUYA Bioscience And Quintiles Announce Partnership For Phase I Development Of New Cancer TherapyHUYA Bioscience Establishes Strategic Partnership With Sun Yat-Sen University’s School Of Pharmaceutical SciencesHUYA Bioscience International And China Medical City Forge Alliance To Help Develop China’s Pharmaceutical IndustryHUYA Bioscience International Strengthens R&D Leadership In Traditional Chinese Medicine With The School Of Chinese Materia Medica, Beijing University Of Chinese MedicineHUYA Bioscience International Establishes Strategic Partnership With School Of Medicine And Pharmacy, Ocean University Of ChinaSolvay Pharmaceuticals Announces Strategic Partnership With HUYA To Access New Drug Candidates From ChinaHUYA Bioscience Announces Strategic Alliance With Abbott On Drug And Biomarker Development Candidates From ChinaHUYA Bioscience Int’l Announces Collaboration Agreement With The Beijing Institute Of Materia Medica, Chinese Academy Of Medical Sciences And Peking Union Medical CollegeHUYA Bioscience Announces Agreement To Provide Schering- Plough With Drug Development Candidates From ChinaHUYA Bioscience Int’l Announces First Pre-IND Outcome For A Development Stage Compound Sourced From China – HBI-8000, Promising New Cancer CompoundHUYA Bioscience Int’l Announces Clinical Trial Milestones In China For Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety ProfileHUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound From The Shanghai Institute Of Materia MedicaHUYA Bioscience International And Chipscreen Biosciences Initiate A Phase I Clinical Cancer TrialHUYA Bioscience Licenses Chidamide Cancer Compound from Chipscreen BiosciencesOrganon Partners With HUYA To Identify And Develop Chinese Biopharmaceuticals
